ATRX - Adhera Therapeutics, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0900
0.0000 (0.00%)
At close: 3:17PM EDT
Stock chart is not supported by your current browser
Previous Close0.0900
Open0.0900
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0800 - 0.0900
52 Week Range0.0700 - 0.5500
Volume20,378
Avg. Volume16,816
Market Cap978,255
Beta (3Y Monthly)2.88
PE Ratio (TTM)N/A
EPS (TTM)-1.6150
Earnings DateNov 18, 2019 - Nov 22, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire

    Adhera Therapeutics Announces Termination of Tender Offer for Preferred Stock

    Adhera Therapeutics, Inc. (ATRX), a specialty pharmaceutical company leveraging technology to commercialize unique therapies and improve patient outcomes, today announced that it has terminated its previously announced offer to exchange all of the outstanding shares of the Series E Convertible Preferred Stock and Series F Convertible Preferred Stock of the Company. As per the terms of the offer, the Company offered, in exchange for each share of preferred stock tendered, such number of shares of the common stock of the Company as is equal to the quotient obtained by dividing (A) the “stated value” of such tendered share of preferred stock by (B) $0.50 (subject to an adjustment mechanism described in the Schedule TO).

  • ACCESSWIRE

    Adhera Therapeutics and Indegene Announce Next Gen Commercialization Partnership

    RESEARCH TRIANGLE PARK, NC / ACCESSWIRE / September 10, 2019 / Adhera Therapeutics, Inc. (ATRX), a specialty pharmaceutical company leveraging technology to commercialize unique therapies and improve patient outcomes, announced today that it has entered into a partnership with Indegene Inc. to deploy the proprietary Indegene co-commercialization model to expand commercialization for its drug, PRESTALIA®, across the United States. PRESTALIA® (https://PRESTALIA-us.net/package-insert) combines two key hypertensive agents, perindopril arginine and amlodipine besylate, and is indicated for the treatment of hypertension.

  • ACCESSWIRE

    Adhera and Allegis Pharma Announce Co-Promotion Agreement

    RESEARCH TRIANGLE PARK, NC / ACCESSWIRE / September 6, 2019 / Adhera Therapeutics, Inc. (ATRX), a specialty pharmaceutical company leveraging technology to commercialize unique therapies and improve patient outcomes, announced today that it has entered into an agreement with Allegis Pharmaceuticals, LLC to co-promote Allegis’ Nitrolingual® Pumpspray, a nitroglycerin lingual spray, indicated for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease. Nitroglycerin is listed as one of the top 300 most prescribed drugs with approximately 3.4 million annual prescriptions in 2016 (https://clincalc.com/DrugStats/Top300Drugs.aspx).

  • GlobeNewswire

    Adhera Therapeutics Appoints Nancy Phelan as Chief Executive Officer

    Adhera Therapeutics, Inc. (ATRX), a specialty pharmaceutical company leveraging technology to commercialize unique therapies and improve patient outcomes, today announced that its Board of Directors has appointed Nancy R. Phelan to serve as Chief Executive Officer of the Company. Ms. Phelan has served as a member of the Board of Directors since October 2018. “I am excited to assume the role of Chief Executive Officer of Adhera Therapeutics,” Ms. Phelan said.

  • ACCESSWIRE

    Adhera Therapeutics' DyrctAxessTM Platform Helps 78% of Patients Adhere to PRESTALIA(R); Achieves Exceptionally High Level of Drug Adherence to an Antihypertensive Medication

    Over 200 prescribers have written at least one prescription for PRESTALIA and over 600 patients are taking the medication PRESTALIA was launched in Q3 2018, powered by the Company's proprietary DyrctAxess ...

  • GlobeNewswire

    Adhera Therapeutics Provides Third Quarter 2018 Financial Results and Business Update

    Research Triangle Park, NC, Nov. 20, 2018 -- Adhera Therapeutics, Inc. (OTCQB: ATRX), an emerging specialty pharmaceutical company commercializing therapies that leverage its.